All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
During the European Hematology Association (EHA) 2023 Hybrid Congress, the AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New York, US. We asked: What were your highlights from EHA 2023?
What were your highlights from EHA 2023?
Roboz begins by summarizing the application of targeted agents to traditional chemotherapy regimens, and how the use of the FLT3 inhibitor midostaurin in the RATIFY trial has paved the way in changing the treatment landscape. Roboz goes on to review the use of gilteritinib in the MORPHO trial, which evaluated maintenance gilteritinib after allogeneic stem cell transplant in patients with FLT3-ITD (internal tandem duplication)–positive acute myeloid leukemia (AML). Roboz also touches on how patients who are measurable residual disease (MRD)-positive have been responding to gilteritinib and the importance of MRD monitoring in patients with FLT3 mutations. Roboz then highlights the need to target the NPM1 mutation in patients with AML, based on late-breaking data gathered from the KOMET-001 trial, where patients with NPM1-mutant relapsed or refractory acute AML have been treated with the Menin inhibitor ziftomenib. Roboz rounds off by mentioning the importance of combining ziftomenib with current upfront therapies to try and prevent relapsed AML.
ASH 2022 abstracts: What’s hot in acute myeloid leukemia?
To help navigate the exciting content being presented at ASH 2022, the AML Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in AML.
Editorial theme | The value of FLT3 targeting in AML
FMS-like tyrosine kinase 3 (FLT3) is a transmembrane protein expressed by hematopoietic stem and progenitor cells and is involved in the early stages of lymphopoiesis and myelopoiesis. FLT3 gene...
Subscribe to get the best content related to AML delivered to your inbox